Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure's proprietary 3-dimensional, spherical nucleic acid (SNAâ˘) architecture unlocks the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure's lead programs address oncology, inflammatory diseases and genetic disorders. Source
No articles found.
With demonstrated clinical development and commercialization expertise, VIVUS is d...
With demonstrated clinical development and comm...
Organogenesis Holdings Inc. is a leading regenerative medicine company focused on ...
Organogenesis Holdings Inc. is a leading regene...
Our mission is to improve the lives of patients by developing novel, best-in-class...
Our mission is to improve the lives of patients...
Albireo is a clinical-stage biopharmaceutical company focused on the development a...
Albireo is a clinical-stage biopharmaceutical c...
Reata is a clinical-stage biopharmaceutical company that develops novel therapeuti...
Reata is a clinical-stage biopharmaceutical com...
Blueprint Medicines is a precision therapy company striving to improve human healt...
Blueprint Medicines is a precision therapy comp...
Global Cancer Technology (GCT) is an emerging medical technology company with nu...
Global Cancer Technology (GCT) is an emerging...
Founded in Lyon, France in 2004, ERYTECH is a clinical-stage biopharmaceutical com...
Founded in Lyon, France in 2004, ERYTECH is a c...
Our strategy is to be known as âthe prostate cancer companyâ. We aspire to be ...
Our strategy is to be known as âthe prostate ...
We are a clinical-stage biopharmaceutical company focused on the development of no...
We are a clinical-stage biopharmaceutical compa...
Join the National Investor Network and get the latest information with your interests in mind.